Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

Stefano Luminari; Luigi Marcheselli; Stefano Sacchi; Sacchi Samantha Pozzi; Alessia Bari; Fiorella Llariucci; Caterina Stelitano; Francesco Angrilli; Antonio Lazzaro; Luca Baldini

doi:10.1002/cncr.24222

Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

Stefano Luminari, Luigi Marcheselli, Stefano Sacchi, Sacchi Samantha Pozzi, Alessia Bari, Fiorella Llariucci, Caterina Stelitano, Francesco Angrilli, Antonio Lazzaro, Luca Baldini

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Recent experience has suggested that there has been a stepwise improvement in the survival outcomes of patients who have follicular lymphoma with the introduction of new treatment options. In the current study, the authors report the results of 2 subsequent phase 2 trials of 238 previously untreated patients. METHODS: In a trial of bleomycin, epidoxorubicin, cyclophosphamide, vincristine, and prednisone (BACOP) plus fludarabine, rnitoxantrone, and dexamethasone (FND), 144 patients received 2 BACOP treatments followed by 4 FND treatments. In a trial of BACOP plus fludarabine and rituximab (FR), 94 patients received 3 BACOP treatments followed by 4 FR treatments. RESULTS: The complete remission

Original language	English
Pages (from-to)	1906-1913
Number of pages	8
Journal	Cancer
Volume	115
Issue number	9
DOIs	https://doi.org/10.1002/cncr.24222
Publication status	Published - May 1 2009

Keywords

Anthracycline
Fludarabine
Follicular lymphoma
Non-hodgkin lymphoma
Rituximab

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1002/cncr.24222

Cite this

@article{5e7034a91bb7421d8d084f340ae26cfb,

title = "Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma",

abstract = "Background: Recent experience has suggested that there has been a stepwise improvement in the survival outcomes of patients who have follicular lymphoma with the introduction of new treatment options. In the current study, the authors report the results of 2 subsequent phase 2 trials of 238 previously untreated patients. METHODS: In a trial of bleomycin, epidoxorubicin, cyclophosphamide, vincristine, and prednisone (BACOP) plus fludarabine, rnitoxantrone, and dexamethasone (FND), 144 patients received 2 BACOP treatments followed by 4 FND treatments. In a trial of BACOP plus fludarabine and rituximab (FR), 94 patients received 3 BACOP treatments followed by 4 FR treatments. RESULTS: The complete remission ",

keywords = "Anthracycline, Fludarabine, Follicular lymphoma, Non-hodgkin lymphoma, Rituximab",

author = "Stefano Luminari and Luigi Marcheselli and Stefano Sacchi and Pozzi, {Sacchi Samantha} and Alessia Bari and Fiorella Llariucci and Caterina Stelitano and Francesco Angrilli and Antonio Lazzaro and Luca Baldini",

year = "2009",

month = may,

day = "1",

doi = "10.1002/cncr.24222",

language = "English",

volume = "115",

pages = "1906--1913",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

AU - Luminari, Stefano

AU - Marcheselli, Luigi

AU - Sacchi, Stefano

AU - Pozzi, Sacchi Samantha

AU - Bari, Alessia

AU - Llariucci, Fiorella

AU - Stelitano, Caterina

AU - Angrilli, Francesco

AU - Lazzaro, Antonio

AU - Baldini, Luca

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Background: Recent experience has suggested that there has been a stepwise improvement in the survival outcomes of patients who have follicular lymphoma with the introduction of new treatment options. In the current study, the authors report the results of 2 subsequent phase 2 trials of 238 previously untreated patients. METHODS: In a trial of bleomycin, epidoxorubicin, cyclophosphamide, vincristine, and prednisone (BACOP) plus fludarabine, rnitoxantrone, and dexamethasone (FND), 144 patients received 2 BACOP treatments followed by 4 FND treatments. In a trial of BACOP plus fludarabine and rituximab (FR), 94 patients received 3 BACOP treatments followed by 4 FR treatments. RESULTS: The complete remission

AB - Background: Recent experience has suggested that there has been a stepwise improvement in the survival outcomes of patients who have follicular lymphoma with the introduction of new treatment options. In the current study, the authors report the results of 2 subsequent phase 2 trials of 238 previously untreated patients. METHODS: In a trial of bleomycin, epidoxorubicin, cyclophosphamide, vincristine, and prednisone (BACOP) plus fludarabine, rnitoxantrone, and dexamethasone (FND), 144 patients received 2 BACOP treatments followed by 4 FND treatments. In a trial of BACOP plus fludarabine and rituximab (FR), 94 patients received 3 BACOP treatments followed by 4 FR treatments. RESULTS: The complete remission

KW - Anthracycline

KW - Fludarabine

KW - Follicular lymphoma

KW - Non-hodgkin lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=65749118604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65749118604&partnerID=8YFLogxK

U2 - 10.1002/cncr.24222

DO - 10.1002/cncr.24222

M3 - Article

C2 - 19248044

AN - SCOPUS:65749118604

SN - 0008-543X

VL - 115

SP - 1906

EP - 1913

JO - Cancer

JF - Cancer

IS - 9

ER -

Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this